Closing Gaps in Uncomplicated UTI Care with Xuron's AI Patient Simulation
FINDING THE GAPS
Challenge
Front‑line clinicians still miss critical steps in diagnosing and treating uncomplicated UTIs (uUTIs). Incomplete histories, imprecise diagnostic language, and non‑guideline antibiotic choices drive recurrent infection and resistance, while weak teach‑back leaves patients confused and non‑adherent.
Solution
A one‑hour accredited experience pairs a 30‑minute rapid‑fire evidence update with a 15‑minute AI‑powered patient simulation and instant feedback book‑ended by pre/post assessments to turn passive knowledge into measurable skill in a single sitting.
110
Clinicians Reached
44
Simulation Participants
4,624
Patients/ Month Impacted
273
Patients/Week Reached
SEE THE DIFFERENCE
Outcomes
Learners gained sharper skills, stronger confidence, and clear growth areas. The program improved diagnosis, treatment, communication, and follow-up with measurable results and revealed key training gaps.
Simulation learners outperform peers by 6–15 points across every metric.
Behavioral Insight
Step‑level analytics expose communication and reasoning gaps, guiding precise remediation.
Confidence Boost
Active practice moves clinicians decisively into "ready‑to‑act" territory.
Scalable Benefit
One hour of training influences care for >4,600 patients each month.
Why it Matters
Whether the setting is clinical, veterinary, administrative or telehealth, a single Xuron simulation session exposes hidden communication gaps—and closes them—faster than any lecture-only approach.
Get the Report
Download the comprehensive 14-page analysis covering methodology, statistical significance testing, and cross-sector implementation insights.
What’s Inside:
Key findings: cross-sector insights, ROI projections, and behavioral patterns driving measurable impact.
Methods and scope: participant demographics, confidence intervals, and course-by-course analysis.
Implementation impact: frameworks for scaling across organizations and sustaining enterprise outcomes.